<DOC>
	<DOCNO>NCT01192295</DOCNO>
	<brief_summary>The purpose study characterize safety oxycodone hydrochloride ( HCl ) controlled-release ( CR ) tablets opioid tolerant pediatric patient age 6 16 year , inclusive , moderate severe malignant and/or nonmalignant pain require opioid therapy .</brief_summary>
	<brief_title>Safety Twice Daily Oxycodone Hydrochloride Controlled-release Tablets Children With Moderate Severe Malignant and/ Nonmalignant Pain Requiring Opioids</brief_title>
	<detailed_description />
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Inclusion Criteria include : Male female patient age 6 16 year , inclusive , expect require ongoing aroundtheclock opioid treatment equivalent least 20mg daily dose oxycodone least 2 week management moderate severe ( base investigator 's judgment ) malignant nonmalignant pain . Patients must opioid tolerant , ie , treated opioids least 5 consecutive day prior dose least 20 mg daily oxycodone equivalent least last 48 hour prior start study drug dose tolerate therapy , demonstrate start study drug dose . Patients currently use transdermal fentanyl patch least 3 day remove patch oxycodone hydrochloride ( HCl ) controlledrelease ( CR ) treatment initiate least 18 hour follow removal transdermal fentanyl patch . Patients must require 240mg total daily dose oxycodone HCl CR tablet . Patients must willing able swallow oxycodone HCl CR tablet whole . Patients must currently investigational medication/therapy start screen study . Exclusion Criteria include : Female patient pregnant lactate . Patients allergic oxycodone history allergy opioids ( criterion include patient experienced common opioid side effect [ eg , nausea , constipation ] ) . Patients receive epidural opioids &lt; 2 hour prior first dose study drug receive epidural morphine &lt; 12 hour prior first dose study drug . Patients contraindicate use opioids . Patients contraindicate blood sampling . Patients currently maintain methadone pain . Patients plan surgery course study , exception placement central peripheral venous access device . Patients surgery within 5 day prior Day 1 ( day first dose study drug ) . Patients , investigator 's opinion , underlie gastrointestinal condition disorder may predispose obstruction . Other protocolspecific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Malignant pain</keyword>
	<keyword>Nonmalignant pain</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Opioid</keyword>
	<keyword>Moderate severe malignant nonmalignant pain</keyword>
</DOC>